期刊文献+

HER2胞外段的克隆与原核表达

Cloning and Prokaryotic Expression of Extracellular Domain of Human Epidermal Growth Factor Receptor 2
下载PDF
导出
摘要 应用RT-PCR技术从人乳腺癌细胞系SK-BR-3中克隆出人表皮生长因子受体2(human epidermal growth factorreceptor 2,HER2)基因的胞外段,并插入到表达载体pET-30a中,得到重组表达载体pET30-HER2(Ex)。将该载体转化至大肠杆菌BL21(DE3)细胞中,加入IPTG进行诱导表达,成功获得HER2胞外段蛋白。分别提取培养液上清、大肠杆菌周质腔、细胞质可溶性及不可溶性组分蛋白进行SDS-PAGE电泳分析,确定目的蛋白定位于大肠杆菌细胞质包涵体中。通过改变诱导温度、诱导物浓度、诱导起始菌体密度和诱导时间,寻找最佳表达条件,使目的蛋白的表达量达到最高。结果表明,在37℃下,OD600达到1.0时,经终浓度为0.1 mmol/L的IPTG诱导4 h,目的蛋白的表达量最高。将重组表达菌进行超声破碎,分离出包涵体组分,经Ni2+亲和层析纯化后获得了纯度>90%的HER2胞外段蛋白,从而为抗HER2抗体的制备及肿瘤疫苗的研究奠定了基础。 Extracellnlar domain gene of Human Epidermal Growth Factor Receptor 2 ( HER2 ) was amplified by RT-PCR from human breast cancer cell line SK-BR-3. The recombinant expression vector pET30-HER2 ( Ex ) was constructed by inserting the extraeellular domain gene of HER2 into the pET-30a vector, and then was transformed into competent E. coli BL21 ( DE3 ) cells. After induced by IPTG, the expression of HER2 extracellular domain protein was obtained in E. coli. Proteins from culture medium fraction, periplasmie fraction, soluble cytoplasmic fraction and inclusion body fraction were extracted and analyzed by SDS-PAGE for the localization of HER2 extraeellular domain protein. Result of SDS-PAGE revealed that HER2 extracellular domain protein localized in the inclusion body of E. coli cytoplasm. Optimum temperature, IPTG concentration, E. coli cell density ( OD60o ) and induction time were determined for the highest production of HER2 extracellular domain protein. The results showed that when OD600 reached 1.0, induced with 0.1 mmol/L IPTG at 37~C for 4 h, where the production of recombinant protein was highest. Recombinant protein in the inclusion body of E. coli was extracted with ultrasonic disruption and was purified by Niz+ affinity chromatography. The obtainment of HER2 extracellnlar domain protein with high purity and high production lays the foundation for the development of anti-HER2 antibody and the study of HER2 overexpressing tumor vaccine.
出处 《生物技术通报》 CAS CSCD 北大核心 2012年第8期88-93,共6页 Biotechnology Bulletin
基金 新乡医学院大学生科研创新重点支助项目(DXSKYKT2010-001)
关键词 人表皮生长因子受体2 胞外结构域 原核表达 pET-30a载体 HER2 Extracellular domain Prokaryotic expression pET-30a vector
  • 相关文献

参考文献9

  • 1Hynes NE, Lane HA. ERBB receptors and cancer : the complexity of targeted inhibitors. Nat Rev Cancer, 2005, 5 ( 5 ) : 341-354.
  • 2Rowinsky EK. The erbB family : targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibody and tyrosine kinase inhibitors. Annu Rev Med, 2004, 55 : 433-457.
  • 3Holbro T, Civenni G, Hynes NE. The ErbB-2 receptor and their role in cancer progression. Exp Cell Res, 2003, 284 ( 1 ) : 99-110.
  • 4Novagen. pET System Manual 8t edition. 1999 : 35-38.
  • 5Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer : correlation of relapse and survival with amplification of the HER- 2/neu oneogene. Science, 1987, 235 ( 4785 ) : 177-182.
  • 6Nahta R, Esteva FJ. Hereeptin : mechanisms of action and resistance. Cancer Lett, 2006, 232( 2 ) : 123-138.
  • 7Disis ML, Knutson KL, Schiffman K, et al. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Tmat, 2000, 62 ( 3 ) : 245-252.
  • 8Bernhard H, Salazar L, Schiffman K, et al. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer, 2002, 9 ( 1 ) : 33-44.
  • 9徐明,郭宁,冯健男,施明,胡美茹,沈倍奋.HER-2/neu胞外配体结合区基因的克隆及原核表达[J].免疫学杂志,2003,19(3):183-185. 被引量:6

二级参考文献10

  • 1Coussens L, Yang Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene [ J]. Science, 1985,230(4 730) : 1132- 1139.
  • 2Brennan PJ, Kumagai T, Berezov A, et al. HER2/neu:mechanisms of dimerization / oligomerization[ J ]. Oncogene,.2000, 19(53) :6093 - 6101.
  • 3Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situhybridization [J]. Proc Natl Acad Sci USA, 1992, 89(12):5321 - 5325.
  • 4Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of c-erbB2 expression in breast cancer[J] .J Surg Oncol, 2002,79(4) :216 - 223.
  • 5Lu J, Cells E. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes[J]. Cancer Res, 2000, 60(18):5223 - 5227.
  • 6Ward RL, Hawkins N J, Coomber D, et al. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer[J]. Hum Immunol, 1999, 60(6) :510 - 515.
  • 7Disis ML, Smith JW, Murphy AE, et al. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein [ J]. Cancer Res,1994, 54(4):1071 - 1076.
  • 8Kono K, Rongcun Y, Charo J, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes[J]. Int J Cancer, 1998, 78(2) :202 - 208.
  • 9Disis ML, Cooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines[J]. J Clin Oneol,2002, 20(11): 2624 -2632.
  • 10Samanta A, LeVea CM, Dougall WC, et al. Ligand and p185c-neu density govem receptor interactions and tyrosine kinase activation [ J ]. Proc Nail Acad Sci USA, 1994,91(5):1711-1715.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部